Open Access

A novel inhibitor of Rho GDP‑dissociation inhibitor α improves the therapeutic efficacy of paclitaxel in Lewis lung carcinoma

  • Authors:
    • Xing Chen Peng
    • Xu Xia Chen
    • Yu Zhang
    • Hai Jun Wang
    • You Feng
  • View Affiliations

  • Published online on: May 27, 2015     https://doi.org/10.3892/br.2015.475
  • Pages: 473-477
  • Copyright: © Peng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Molecular‑targeted therapies are considered a promising strategy for the treatment of most types of human cancer. Rho GDP‑dissociation inhibitor α (RhoGDIα), which functions mainly by controlling the cellular distribution and activity of Rho GTPases and is associated with tumor progression and poor prognosis of cancer patients, has become a new promising target for anticancer treatment. Recently, a specific RhoGDIα inhibitor (no. SKLB‑163) was developed via computer‑aided drug design and de novo synthesis. Previous studies have shown that SKLB‑163 had extremely good antitumor activities against diverse cancer cell lines. In the present study, SKLB‑163 was used in combination with paclitaxel in order to determine the synergistic effect of the antitumor activity. The findings showed that the combination therapy clearly inhibited cell proliferation and induced apoptosis of LL/2 in vitro. The LL/2 mice model also showed that the combination therapy inhibited tumor growth in vivo. Proliferative cell nuclear antigen (PCNA) immunohistochmeistry and terminal deoxynucleotidyl transferase dUTP nick end‑labeling showed that combination therapy inhibited cell proliferation and increased apoptosis compared to the treatment with SKLB‑163 or paclitaxel alone. The data suggests that the combination therapy exerted synergistic antitumor effects, providing a novel way to augment the antitumor efficacy of cytotoxic chemotherapy.
View Figures
View References

Related Articles

Journal Cover

July-2015
Volume 3 Issue 4

Print ISSN: 2049-9434
Online ISSN:2049-9442

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Peng XC, Chen XX, Zhang Y, Wang HJ and Feng Y: A novel inhibitor of Rho GDP‑dissociation inhibitor α improves the therapeutic efficacy of paclitaxel in Lewis lung carcinoma. Biomed Rep 3: 473-477, 2015
APA
Peng, X.C., Chen, X.X., Zhang, Y., Wang, H.J., & Feng, Y. (2015). A novel inhibitor of Rho GDP‑dissociation inhibitor α improves the therapeutic efficacy of paclitaxel in Lewis lung carcinoma. Biomedical Reports, 3, 473-477. https://doi.org/10.3892/br.2015.475
MLA
Peng, X. C., Chen, X. X., Zhang, Y., Wang, H. J., Feng, Y."A novel inhibitor of Rho GDP‑dissociation inhibitor α improves the therapeutic efficacy of paclitaxel in Lewis lung carcinoma". Biomedical Reports 3.4 (2015): 473-477.
Chicago
Peng, X. C., Chen, X. X., Zhang, Y., Wang, H. J., Feng, Y."A novel inhibitor of Rho GDP‑dissociation inhibitor α improves the therapeutic efficacy of paclitaxel in Lewis lung carcinoma". Biomedical Reports 3, no. 4 (2015): 473-477. https://doi.org/10.3892/br.2015.475